Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $171000.0.

  • Allogene Therapeutics' Capital Expenditures fell 6013.99% to $171000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $643000.0, marking a year-over-year increase of 404.53%. This contributed to the annual value of $694000.0 for FY2024, which is 5422.16% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Capital Expenditures stood at $171000.0, which was down 6013.99% from $116000.0 recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Capital Expenditures high stood at $9.1 million for Q2 2021, and its period low was $8000.0 during Q1 2024.
  • Its 5-year average for Capital Expenditures is $1.6 million, with a median of $358500.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Capital Expenditures was 347500.0% (2024), while the steepest drop was 9922.71% (2024).
  • Allogene Therapeutics' Capital Expenditures (Quarter) stood at $736000.0 in 2021, then soared by 129.89% to $1.7 million in 2022, then crashed by 89.3% to $181000.0 in 2023, then surged by 41.99% to $257000.0 in 2024, then crashed by 33.46% to $171000.0 in 2025.
  • Its Capital Expenditures stands at $171000.0 for Q3 2025, versus $116000.0 for Q2 2025 and $99000.0 for Q1 2025.